

## Corgenix Medical Corp (CONX)

### Company Overview

Corgenix Medical Corporation ("Corgenix") holds a unique position and is an undisputed leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for determining the effectiveness of aspirin. Corgenix also has an ever increasing presence in the detection of emerging pathogens, including bio-threat agents. As a result of this focus, the company has become one of the foremost experts in the diagnosis and measuring of various components of the blood coagulation (clotting) system, measuring the risk of vascular occlusion and thrombotic risk factors.

Corgenix provides worldwide marketing for these products through both direct and indirect sales and distribution channels. Since its inception in 1990, Corgenix has demonstrated a strong and continued growth in this market and has a formidable reputation as an innovative provider of healthcare products. Our menu of over 52 diagnostic products is sold on a worldwide basis to hospitals, clinical laboratories, commercial reference laboratories, and research institutions. Corgenix was the first commercial company in the United States to develop and manufacture the anticardiolipin assay used in the detection of a number of autoimmune and vascular diseases. Since 1990 the Corgenix product line has grown to include products used in the diagnosis of four important areas of healthcare: autoimmune disease, vascular disease, infectious disease and liver disease.

The company's expertise in advancing products through the FDA process, key strategic partnerships, an expanded global distribution network, significant underutilized manufacturing capabilities, and a management team with many years of relevant experience and a solid record of commercial execution, all afford tremendous growth potential for the company in all business areas.

Price	\$ 0.10
Change	-11.27%
Volume	8,000
52 Week High	\$ 0.19
52 Week Low	\$ 0.0751
EPS	\$ -0.0014
PE Ratio	0.00
Shares Outstanding	46.42 M
Market Cap	4.64 M

Data as of May 21, 2012 ET



### Recent Financial News

Date	Headline
May 14, 2012	Corgenix Reports Record Quarterly Sales Results
May 1, 2012	Corgenix to Host Conference Call to Discuss Third Quarter Results
Feb 15, 2012	Corgenix Automated Hyaluronic Acid (HA) Test Kit Now CE Marked
Feb 14, 2012	Corgenix Reports Second Quarter Fiscal 2012 Financial Results
Feb 3, 2012	Corgenix to Host Conference Call to Discuss Second Quarter Results

### Recent SEC Filings

Date	Type	Description
May 14, 2012	10-Q	Quarterly report
Feb 14, 2012	10-Q	Quarterly report
Jan 18, 2012	S-8	Securities to be offered to employees in employee benefit plans
Jan 17, 2012	8-K	Current report
Dec 5, 2011	DEF 14A	Other definitive proxy statements

Copyright ©2012 Issuer Direct Corporation (ISDR) All rights reserved. To request a copy of this report, report a problem, or to inquire about another report please contact our client services group 919.481.4000. Stock information presented is at least 20-minutes delayed.

## Corgenix Medical Corp (CONX)

### Management Team

**Douglass T. Simpson**  
President, Chief Executive Officer

**William H. Critchfield**  
SVP Operations and Finance and Chief Financial Officer

**Ann L. Steinbarger**  
SVP Sales and Marketing

**Luis R. Lopez, M.D.**  
Chief Medical Officer

**Taryn G. Reynolds**  
VP Facilities and IT

### Board of Directors

**Stephan P. Gouze**  
Chairman

**Luis Lopez, MD**  
Director

**Robert Tutag**  
Director

**Dennis Walczewski**  
Director

**David Ludvigson**  
Director

**Bruce A. Huebner**  
Director

**Douglass Simpson**  
Director

### Contact Information

William H. Critchfield  
SVP/CFO  
11575 Main Street, Suite 400  
Broomfield, CO 80020  
(303) 453-8903

Auditors  
Hein & Associates  
717 17th Street Suite 1600  
Denver, CO 80202  
(303) 298-9601